Filing Details
- Accession Number:
- 0001209191-17-058479
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-10-31 18:15:02
- Reporting Period:
- 2017-10-31
- Accepted Time:
- 2017-10-31 18:15:02
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1610876 | Jeffrey Chodakewitz | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp Gmda, Cmo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2017-10-31 | 1,400 | $142.38 | 113,024 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-10-31 | 4,100 | $143.46 | 108,924 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-10-31 | 25,784 | $144.46 | 83,140 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-10-31 | 19,016 | $145.26 | 64,124 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-10-31 | 4,700 | $146.52 | 59,424 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-10-31 | 3,400 | $147.75 | 56,024 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-10-31 | 1,400 | $148.40 | 54,624 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-10-31 | 200 | $149.34 | 54,424 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $142.38 (range $141.83 to $142.81).
- Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $143.46 (range $142.87 to $143.85).
- Open market sales reported on this line occurred at a weighted average price of $144.46 (range $143.90 to $144.89).
- Open market sales reported on this line occurred at a weighted average price of $145.26 (range $144.91 to $145.87).
- Open market sales reported on this line occurred at a weighted average price of $146.52 (range $146.16 to $147.14).
- Open market sales reported on this line occurred at a weighted average price of $147.75 (range $147.18 to $148.15).
- Open market sales reported on this line occurred at a weighted average price of $148.40 (range $148.19 to $148.70).
Billionaire Hedge Funds
